Elena Cortizas

Mrs. Elena Cortizas

University of Miami, Sylvester Comprehensive Cancer Center
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JPJennifer Permuth
Jennifer Permuth
KDKaleena Dezsi
Kaleena Dezsi
SVShraddha Vyas
Shraddha Vyas
KAKarla N. Ali
Karla N. Ali
TBToni L. Basinski
Toni L. Basinski
OCon behalf of the Florida Pancreas Collaborative
on behalf of the Florida Pancreas Collaborative
Background: Well-annotated, high-quality biorepositories provide a valuable platform to support translational research. However, most biorepositories have poor representation of minority groups, limiting the ability to address health disparities. Methods: We describe the establishment of the Florida Pancreas Collaborative (FPC), the first state-wide prospective cohort study and biorepository designed to address the higher burden of pancreatic cancer (PaCa) in African Americans (AA) compared to Non-Hispanic Whites (NHW) and Hispanic/Latinx (H/L). We provide an overview of stakeholders; study eligibility and design; recruitment strategies; standard operating procedures to collect, process, store, and transfer biospecimens, medical images, and data; our cloud-based data management platform; and progress regarding recruitment and biobanking. Results: The FPC consists of multidisciplinary teams from fifteen Florida medical institutions. From March 2019 through August 2020, 350 patients were assessed for eligibility, 323 met inclusion/exclusion criteria, and 305 (94%) enrolled, including 228 NHW, 30 AA, and 47 H/L, with 94%, 100%, and 94% participation rates, respectively. A high percentage of participants have donated blood (87%), pancreatic tumor tissue (41%), computed tomography scans (76%), and questionnaires (62%). Conclusions: This biorepository addresses a critical gap in PaCa research and has potential to advance translational studies intended to minimize disparities and reduce PaCa-related morbidity and mortality.

24 June 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
EDEvan Davis
Evan Davis
MPMargaret A. Park
Margaret A. Park
TBToni L. Basinski
Toni L. Basinski
JAJ. Pablo Arnoletti
J. Pablo Arnoletti
MBMark Bloomston
Mark Bloomston
FCfor the Florida Pancreas Collaborative
for the Florida Pancreas Collaborative
Background: Muscle loss influences pancreatic ductal adenocarcinoma (PDAC) outcomes, but treatment-related edema may cause overestimation of total skeletal muscle area (tSMA), confounding our understanding of muscle changes. However, no studies have quantified the impact of edema on tSMA and psoas skeletal muscle area (pSMA) changes. Thus, we sought to (i) assess the impact of edema on tSMA and pSMA changes between diagnosis and follow-up and (ii) explore the utility of pSMA as a clinically relevant measure of muscle and muscle loss among patients with PDAC. Methods: Body composition was measured using CT scans at diagnosis and follow-up from 95 patients enrolled in the Florida Pancreas Collaborative cohort study. Edema was assessed by opacifications in subcutaneous fat, and tSMA and pSMA changes were expressed as percent change between diagnosis and follow-up. We used multivariable generalized linear models to estimate mean tSMA and pSMA changes overall and by edema status. Spearman correlation was used to measure interrelationships of tSMA and pSMA. Results: tSMA increased between diagnosis and follow-up (Δ = 0.66) but only in patients with edema (Δ = 3.35) whereas non-edematous patients lost tSMA (Δ = −2.03). Conversely, pSMA decreased regardless of edema status. Furthermore, tSMA and pSMA were strongly correlated overall (r = 0.75) and in non-edematous patients (r = 0.83). Conclusions: Edema inflated estimates of tSMA at follow-up in patients with PDAC, but pSMA was impervious to edema and may represent a suitable proxy for tSMA. Impact: pSMA is a reliable measure of muscle and muscle loss and should be considered in future studies assessing muscle loss in patients with PDAC.

2 September 2025
Verified
Other
Open access
PDF file
EDEvan Davis
Evan Davis
MPMargaret A. Park
Margaret A. Park
TBToni L. Basinski
Toni L. Basinski
JAJ. Pablo Arnoletti
J. Pablo Arnoletti
MBMark Bloomston
Mark Bloomston
JPJennifer Permuth
Jennifer Permuth
Results of the change-in-estimate assessment of confounding.

2 September 2025
Verified
Other
Open access
PDF file
EDEvan Davis
Evan Davis
MPMargaret A. Park
Margaret A. Park
TBToni L. Basinski
Toni L. Basinski
JAJ. Pablo Arnoletti
J. Pablo Arnoletti
MBMark Bloomston
Mark Bloomston
JPJennifer Permuth
Jennifer Permuth
Forest plots of tSMA and pSMA changes and mortality.

2 September 2025
Verified
Other
Open access
PDF file
EDEvan Davis
Evan Davis
MPMargaret A. Park
Margaret A. Park
TBToni L. Basinski
Toni L. Basinski
JAJ. Pablo Arnoletti
J. Pablo Arnoletti
MBMark Bloomston
Mark Bloomston
JPJennifer Permuth
Jennifer Permuth
Select clinical and epidemiological characteristics of the study population of all PDAC patients in the FPC Cohort and according to those included versus excluded in the current analysis.

2 September 2025
Verified
Other
Open access
PDF file
EDEvan Davis
Evan Davis
MPMargaret A. Park
Margaret A. Park
TBToni L. Basinski
Toni L. Basinski
JAJ. Pablo Arnoletti
J. Pablo Arnoletti
MBMark Bloomston
Mark Bloomston
JPJennifer Permuth
Jennifer Permuth
Mean total skeletal muscle area (tSMA) and psoas skeletal muscle area (pSMA) at diagnosis and follow-up among PDAC cohort participants overall and according to edema status.